A theranostic "SMART" aptamer for targeted therapy of prostate cancer.
作者信息
de Franciscis Vittorio
机构信息
Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, Naples, Italy.
出版信息
Mol Ther. 2014 Nov;22(11):1886-8. doi: 10.1038/mt.2014.190.
Abstract
摘要
相似文献
1
A theranostic "SMART" aptamer for targeted therapy of prostate cancer.一种用于前列腺癌靶向治疗的诊疗一体化“智能”适配体。
Mol Ther. 2014 Nov;22(11):1886-8. doi: 10.1038/mt.2014.190.
2
Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.用一种针对前列腺特异性膜抗原的RNA适配体对前列腺癌转移进行靶向抑制。
Mol Ther. 2014 Nov;22(11):1910-22. doi: 10.1038/mt.2014.117. Epub 2014 Jun 23.
3
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.第二代适体偶联 PSMA 靶向递药系统用于前列腺癌治疗。
Int J Nanomedicine. 2011;6:1747-56. doi: 10.2147/IJN.S23747. Epub 2011 Aug 19.
4
Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?推动PSMA靶向诊疗技术走向临床：常识能否占上风？
J Nucl Med. 2017 Aug;58(8):1186-1187. doi: 10.2967/jnumed.117.193516. Epub 2017 May 4.
5
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.靶向前列腺特异性膜抗原（PSMA）的放射性标记酶抑制剂和结合剂：用于前列腺癌成像和治疗的有效诊疗工具。
Nucl Med Biol. 2016 Nov;43(11):692-720. doi: 10.1016/j.nucmedbio.2016.08.006. Epub 2016 Aug 11.
6
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.核医学的新视角：拓展前列腺特异性膜抗原（PSMA）靶向成像与治疗的适应症
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613. doi: 10.1007/s00259-017-3767-4. Epub 2017 Jul 4.
7
Will GRPR Compete with PSMA as a Target in Prostate Cancer?胃泌素释放肽受体（GRPR）会成为前列腺癌中与前列腺特异性膜抗原（PSMA）竞争的靶点吗？
J Nucl Med. 2017 Dec;58(12):1883-1884. doi: 10.2967/jnumed.117.198192. Epub 2017 Sep 28.
8
Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide--glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer.负载紫杉醇且靶向A10-3.2适配体的聚（丙交酯-乙交酯）纳米泡用于前列腺癌的超声成像与治疗
Int J Nanomedicine. 2017 Jul 26;12:5313-5330. doi: 10.2147/IJN.S136032. eCollection 2017.
9
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.通过PET成像评估的PSMA表达是选择任何PSMA靶向治疗患者所需的生物标志物。
J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159.
10
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.使用靶向 PSMA 适体 A10-3.2 的脂质纳米气泡诊断前列腺癌。
Int J Nanomedicine. 2016 Aug 12;11:3939-50. doi: 10.2147/IJN.S112951. eCollection 2016.
引用本文的文献
1
In vitro selection of DNA aptamers against human osteosarcoma.体外筛选抗人骨肉瘤的 DNA 适体。
Invest New Drugs. 2022 Feb;40(1):172-181. doi: 10.1007/s10637-021-01161-y. Epub 2021 Aug 12.
2
Aptamers used for biosensors and targeted therapy.适体在生物传感器和靶向治疗中的应用。
Biomed Pharmacother. 2020 Dec;132:110902. doi: 10.1016/j.biopha.2020.110902. Epub 2020 Oct 20.
3
Integrin Inhibitors in Prostate Cancer.前列腺癌中的整合素抑制剂
Cancers (Basel). 2018 Feb 6;10(2):44. doi: 10.3390/cancers10020044.
4
Metal-Based PSMA Radioligands.基于金属的前列腺特异性膜抗原放射性配体
Molecules. 2017 Mar 24;22(4):523. doi: 10.3390/molecules22040523.
本文引用的文献
1
Oligonucleotide aptamers: new tools for targeted cancer therapy.寡核苷酸适体：靶向癌症治疗的新工具。
Mol Ther Nucleic Acids. 2014 Aug 5;3(8):e182. doi: 10.1038/mtna.2014.32.
2
Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.用一种针对前列腺特异性膜抗原的RNA适配体对前列腺癌转移进行靶向抑制。
Mol Ther. 2014 Nov;22(11):1910-22. doi: 10.1038/mt.2014.117. Epub 2014 Jun 23.
3
Oncology drug discovery: planning a turnaround.肿瘤药物研发：规划转机。
Cancer Discov. 2014 Apr;4(4):397-404. doi: 10.1158/2159-8290.CD-13-0452.
4
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.靶向转移性去势抵抗性前列腺癌：进展机制与新型早期治疗方法
Expert Opin Investig Drugs. 2014 Apr;23(4):469-87. doi: 10.1517/13543784.2014.885950. Epub 2014 Feb 3.
5
Antibody-drug conjugates targeting prostate-specific membrane antigen.针对前列腺特异性膜抗原的抗体药物偶联物。
Front Biosci (Landmark Ed). 2014 Jan 1;19(1):12-33. doi: 10.2741/4193.
6
Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.PSMA×CD3 双抗体通过重定向 T 细胞裂解前列腺癌细胞的抗肿瘤活性。
Immunotherapy. 2013 Jan;5(1):27-38. doi: 10.2217/imt.12.136.
7
Monoclonal antibodies in cancer therapy.癌症治疗中的单克隆抗体。
Cancer Immun. 2012;12:14. Epub 2012 May 1.
8
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.前列腺特异性膜抗原可以促进小鼠体内前列腺癌细胞的骨转移。
Braz J Med Biol Res. 2012 Aug;45(8):737-45. doi: 10.1590/s0100-879x2012007500085. Epub 2012 May 17.
9
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.使用计算结构建模合理截短针对前列腺特异性膜抗原的 RNA 适体。
Nucleic Acid Ther. 2011 Oct;21(5):299-314. doi: 10.1089/nat.2011.0313.
10
Targeting cancer cells with nucleic acid aptamers.用核酸适体靶向癌细胞。
Trends Biotechnol. 2010 Oct;28(10):517-25. doi: 10.1016/j.tibtech.2010.07.005. Epub 2010 Aug 17.
Zotero 插件